Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera

AIDS Research and Human Retroviruses

Volumn 15, Issue 7, 1999, Pages 671-677

  Metlas, R ^a,b,d   Trajkovic, D ^c,d   Srdic, T ^a,b,d   Veljkovic, V ^a,b   Colombatti, A ^d,e  

^a R and D Institute   (Serbia)

^b Diapharm Ltd   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; VIRUS GLYCOPROTEIN;

ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOREACTIVITY; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SERODIAGNOSIS;

EID: 0033136047     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310971     Document Type: Article

References (38)

1. Berzofsky JA: Approaches and issues in the development of vaccines against HIV. J AIDS 1990;4:451-456.
2. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, and Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
3. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, and Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249: 932-935.
4. Weber J., Fenyö E-M, Beddows S, Kaleebu P, Bjorndal A, and the WHO Network for HI Isolation and Characterization: Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J Virol 1996;70:7827-7832.
5. Moore JP, Cao Y, Leu J, Qin L, Korber B, and Ho DD: Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70: 427-444.
6. Nyambi PN, Nkengasong J, Lewi P, Koen A, Janssens W, Fransen K, Heyndricks L, Piot P, and van der Groen G: Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996;70:445-458.
7. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Brudac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, and Burke DS: Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 1996;12: 1319-1328.
8. Bou-Habib DC, Rodriquez G, Oravecz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
9. Broder CC, Earl PL, Long D, Abedon ST, Moss B, and Doms RW: Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;91: 11699-11703.
10. Turbica I, Simon F, Besnier JM, LeJeune B, Choutet P, Goudeau A, and Barin F: Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection. J Med Virol 1997;52:309-315.
11. Kohler H, Muller S, and Nara PL: Deceptive imprinting in the immune response against HIV-1. Immunol Today 1994;15:475-478.
12. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
13. Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, Paolucci S, Daucher MB, Cohen OJ, Denis F, Biddison WE, Sekaly RP, and Fauci AS: Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997;94:9848-9853.
14. Moore J and Trkola A: HIV Type 1 coreceptors, neutralization serotypes and vaccine development. AIDS Res Hum Retroviruses 1997;13:733-736.
15. Rodman TC, To SE, Hashish H, and Manchester K: Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA 1993;90:7719-7723.
16. Townsley-Fuchs J, Kam L, Fairhurst R. Gane SJ, Goodglick L, Giorgi JV, Sidell N, Detes R, and Braun J: Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies: A host factor in homosexual HIV-1 transmission. J Clin Invest 1996;98:1794-1801.
17. Douvas A, Takehana Y, Ehresmann G, Chernyovskiy T, and Daar ES: Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease. AIDS Res Hum Retroviruses 1996;12:1509-1517.
18. Singh RR, Ebling FM, Sercarz EE, and Hahn BH: Immune tolerance to autoantibody-dependent peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995;96:2990-2996.
19. Metlas R, Veljkovic V, Paladini DR, and Pongor S: Protein and DNA sequence homology between the V3 loop of human immunodeficiency virus type 1 envelope protein gp120 and immunoglobulin variable region. Biochem Biophys Res Commun 1991;179:1056-1062.
20. Veljkovic V and Metlas R: Identification of immunoglobulin recombination elements in HTV-1 envelope gene. Immunol Lett 1991;31:11-14.
21. Veljkovic V and Metlas R: HIV and idiotypic T-cell regulation: Another view. Immunol Today 1992;13:38.
22. Metlas R, Skerl V, Veljkovic V, Colombatti A, and Pongor S: Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Viral Immunol 1994;7:215-219.
23. Metlas R and Veljkovic V: Does HIV-1 gp120 manipulate human immune network. Vaccine 1995;13:355-359.
24. Coutinho A, Kazatchkine MD, and Avrameas S: Natural autoantibodies. Curr Opin Immunol 1995;7:812-818.
25. Bona CA: V genes encoding autoantibodies: Molecular and phenotypic characteristics. Annu Rev Immunol 1988;6:327-358.
26. Cohen IR and Cooke A: Natural autoantibodies might prevent autoimmune disease. Immunol Today 1986;7:363-364.
27. NY5 glycoprotein 120 V3 loop and consensus sequence of collagens. AIDS Res Hum Retroviruses 1994;10:1425-1426.
28. Fraziano M, Montesano C, Lombardi VRM, Marchione OP, and Colizzi V: The presence of antibodies against HIV peptides in the sera of alloimmune mice and thalassemic patients is due to a polyclonal activation mechanism. Clin Immunol Immunopathol 1997; 84:202-207.
29. Veljkovic V and Metlas R: Identification of nonapeptide from HTLV3, LAV and ARV-2-envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem Biophys 1988;10: 191-206.
30. Veljkovic V, Metlas R, Raspopovic J, and Pongor S: Spectral and sequence similarity between vasoactive intestinal peptide and second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): Possible consequences on prevention and therapy of AIDS. Biochem Biophys Res Commun 1992; 189:705-710.
31. Schreiber M, Wachsmuth C, Muller H, Odemuyiwa S, Schmitz H, Meyer S, Meyer B, and Schneider-Mergerer J: The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed agaisnt a variable, discontinous epitope presented by the gp120 V3 domain. J Virol 1997;71: 9198-9205.
32. Kent KA and Robinson J: Antigenic determinants on HTV-1 envelope glycoproteins: A dickens of a time with an oligomer twist. AIDS 1996;10(Suppl. A):S107-S114.
33. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G de Jong, Goudsmit J, and Nara PL: Refocusing neutralizing antibody response by target dampening of an immunodominant epitope. J Immunol 1997;159:279-289.
34. Veljkovic V, Johnson E, and Metlas R: Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. Vaccine 1997;15: 473-174.
35. Veljkovic V, Johnson E, and Metlas R: Analogy of HIV-1 to oncogenic viruses: Possible implications for the pathogenesis of AIDS. Cancer J 1995;8:308-314.
36. Silvestris F, Williams RC, and Dammacco F: Short analytical review. Autoreactivity in HIV-1 infection: The role of molecular mimicry. Clin Immunol Immunopathol 1995;41:197-205.
37. Susal C, Kropelin M, Daniel V, and Opelz G: Molecular mimicry between HIV-1 and antigen receptor molecules: A clue to the pathogenesis of AIDS. Vox Sang 1993;65:10-17.
38. Wang H, Muler S, Zolla-Pazner S, and Kohler H: Human monoclonal and polyclonal antihuman immunodeficiency virus-1 antibodies share in a common clonotypic specificity. Eur J Immunol 1992;22:1749-1755.